The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | PROs from DeLLphi-304 evaluating tarlatamab vs chemotherapy in SCLC
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, discusses patient-reported outcomes from Phase III DeLLphi-304 (NCT05740566) of tarlatamab versus chemotherapy in previously treated small cell lung cancer (SCLC). Improvements in symptoms such as dyspnea, cough, and chest pain were reported in the tarlatamab arm, along with better physical functioning, global health status, and reduced treatment burden. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Certainly, I had the pleasure to present in a poster in this Congress, the patient-reported outcomes of the large registrational trial DeLLphi-304. May I remind you that this was a trial in extensive-stage, small-cell lung cancer, second-line, so pre-treated patients with chemoimmunotherapy that were randomized to receive either tarlatamab or standard second-line chemotherapy, comprising either Topotecan or Lurbinectedin or Amrubicin...
Certainly, I had the pleasure to present in a poster in this Congress, the patient-reported outcomes of the large registrational trial DeLLphi-304. May I remind you that this was a trial in extensive-stage, small-cell lung cancer, second-line, so pre-treated patients with chemoimmunotherapy that were randomized to receive either tarlatamab or standard second-line chemotherapy, comprising either Topotecan or Lurbinectedin or Amrubicin. So the trial was highly significant for its primary endpoint, overall survival, and in this analysis that was presented in this congress we concentrated on patient-reported outcomes that were a key secondary endpoint of the trial and what we saw is that tarlatamab was associated with a statistically significant improvement in critical signs and symptoms related to small-cell lung cancer such as dyspnea, cough and also a numerical improvement in other symptoms that are really bothersome like chest pain. And overall, Tarlatamab delayed the deterioration of the overall quality of life and the exacerbation of those symptoms as compared to standard second-line chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
